Premium
Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin‐targeted therapies
Author(s) -
Hu Zishuo I.,
Ghafoor Azam,
Sengupta Manjistha,
Hassan Raffit
Publication year - 2021
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.33433
Subject(s) - medicine , pemetrexed , mesothelin , mesothelioma , nivolumab , oncology , durvalumab , ipilimumab , immunotherapy , food and drug administration , cancer , chemotherapy , cisplatin , pathology , pharmacology
Malignant mesothelioma is an aggressive cancer with a poor prognosis and limited treatment options. For many years, the only US Food and Drug Administration‐approved first‐line treatment for unresectable mesothelioma was pemetrexed plus cisplatin. However, the recent approval of nivolumab plus ipilimumab as frontline treatment for patients with pleural mesothelioma marks a significant milestone for the treatment of this disease. In this review, the authors describe recent advances in therapeutic strategies for the treatment of patients with advanced, unresectable mesothelioma, highlighting the emerging use of immunotherapy and mesothelin‐targeted therapies for the management of malignant mesothelioma.